IDEXX Laboratories, Inc. $IDXX Holdings Cut by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 54,668 shares of the company’s stock after selling 1,169 shares during the period. Asset Management One Co. Ltd. owned about 0.07% of IDEXX Laboratories worth $37,601,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of IDXX. Vanguard Group Inc. raised its holdings in shares of IDEXX Laboratories by 0.9% during the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock worth $6,364,638,000 after acquiring an additional 86,040 shares in the last quarter. Bank of New York Mellon Corp grew its stake in IDEXX Laboratories by 41.7% in the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after purchasing an additional 605,290 shares in the last quarter. Invesco Ltd. increased its position in IDEXX Laboratories by 14.0% in the 3rd quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock worth $843,503,000 after purchasing an additional 161,782 shares during the last quarter. Principal Financial Group Inc. increased its position in IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after purchasing an additional 187,967 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of IDEXX Laboratories by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after purchasing an additional 326,348 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares in the company, valued at $54,975,125.30. This trade represents a 21.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Nimrata Hunt sold 2,693 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the transaction, the executive vice president directly owned 19,899 shares of the company’s stock, valued at approximately $13,163,984.46. This represents a 11.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock worth $29,862,109 in the last ninety days. 0.79% of the stock is owned by insiders.

IDEXX Laboratories Stock Up 3.4%

Shares of IDEXX Laboratories stock opened at $589.25 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $402.85 and a 12-month high of $769.98. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock has a 50 day moving average price of $601.30 and a two-hundred day moving average price of $654.97. The stock has a market capitalization of $46.80 billion, a P/E ratio of 45.08, a PEG ratio of 3.46 and a beta of 1.72.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm posted $2.53 earnings per share. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IDXX. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. BTIG Research cut their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. UBS Group reduced their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday. They issued a “neutral” rating and a $650.00 target price for the company. Finally, Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $760.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.